Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806554 · ClinicalTrials.gov registry record
Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial
A clinical trial of Diabetes Mellitus, sponsored by Sinocare.
- Completed
- Registry status
- 159
- Enrollment target
- 6
- Study locations
NCT05806554: Completed study of Diabetes Mellitus, sponsored by Sinocare.
NCT05806554 is a study of Diabetes Mellitus that has completed, run by Sinocare. The registered enrollment target is 159 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05806554, a study of Diabetes Mellitus, has completed, sponsored by Sinocare.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.
Primary Outcome
percentage of iCGM values in the measuring range less than 70 mg/dL (3.9 mmol/l) within +/- 15 mg/dL (0.83 mmol/l) of the
Conditions Studied
Interventions
- DEVICE Continuous glucose monitoring device
Study Locations (6)
Other
- PSHI Praxis GmbH - Mainz
- Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm - Ulm
Arkansas
- Woodland Research Northwest - Rogers
California
- Diablo Clinical Research - Walnut Creek
Georgia
- Atlanta Diabetes Associates - Atlanta
Washington
- Rainier Clinical Research Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2024-10-22 |
What the finished NCT05806554 record still lists
NCT05806554 is an observational study that tracks outcomes without assigning an intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Continuous glucose monitoring device is the first listed.
NCT05806554 lists 6 locations in 5 states (Other, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT05806554 about?
NCT05806554 is a clinical study titled "Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial". The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.
What is the current status of trial NCT05806554?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2023-07-19. Estimated completion is 2024-10-22.
What conditions does trial NCT05806554 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT05806554?
The interventions under investigation include: Continuous glucose monitoring device (DEVICE).
Who is sponsoring clinical trial NCT05806554?
This trial is sponsored by Sinocare, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806554 being conducted?
This trial has 6 study locations across Arkansas, California, Georgia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05806554's enrollment target sits among peer trials
159 98th of 208 higher than 111 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Genetic Studies of Insulin and Diabetes
RECRUITING
-
Improving Glycemic Control With Telemedicine and Smart Insulin Pens
RECRUITING · NA
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI